🏛️ Verified NIH Record • Updated 2025-12-10
Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer (NCT05296512)
A Phase II Trial of Pembrolizumab and Lenvatinib in Patients With Recurrent or Persistent Clear Cell Carcinoma of the Ovary
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Elizabeth K. Lee MD
🩺 Plain-English Summary (8th-Grade Level)
This research study is being done to test the efficacy and safety of combining the study drugs pembrolizumab and lenvatinib in patients with clear cell ovarian cancer. The names of the study drugs involved in this study are: * Lenvatinib * Pembrolizumab
Who can join: Review the eligibility criteria below.
Location: University of Chicago Medicine — Chicago, Illinois
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (3 Sites)
- University of Chicago Medicine — Chicago, Illinois
- Dana Farber Cancer Institute — Boston, Massachusetts
- Mayo Clinic Comprehensive Cancer Center — Rochester, Minnesota
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Ovarian Clear Cell Carcinoma
Explore by condition: All Ovarian Clear Cell Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.